Selpercatinib for previously untreated medullary thyroid cancer with RET mutation in patients ages 12 and older

Selpercatinib is in clinical development for the treatment of medullary thyroid cancer (MTC) with RET mutation in people aged 12 and older. Thyroid cancer is a malignant neoplasm that originates from cells in the thyroid gland located in the front of the neck. MTC is a cancer that forms inside the thyroid in the medulla. The majority of MTC have a mutation in the RET gene which leads to an overactive process that causes the cancer cells to grow uncontrolled. In advanced MTC, the primary treatment is extensive surgical resection with curative intent. Around 10% of these will progress to advanced disease where there are limited first-line systemic options available.